BeiGene appoints ex-Sanofi CEO Olivier Brandicourt to board; director Malley resigns

BeOne Medicines Ltd.

Thomas Malley resigned from BeiGene board and audit committee on Jan 22, 2024; no disagreement with company operations.
Olivier Brandicourt, former Sanofi CEO and Blackstone Life Sciences Senior Advisor, appointed to board on Jan 23, 2024.
Brandicourt will serve on audit committee and receive annual cash comp of $65,000 plus $17,500 for committee service, and pro-rated option valued at $400,000.
He fills the vacancy created by Malley's resignation and will stand for election at the 2024 annual meeting in June.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Olivier Brandicourt

Director

ONC · BeOne Medicines Ltd.

Effective: 2024-01-23
Filed: January 23, 2024, 6:59 PM ET

On January 23, 2024, the Board appointed Olivier Brandicourt, M.D. to the Board to fill the vacancy.

Departed

Thomas Malley

Director

ONC · BeOne Medicines Ltd.

Effective: 2024-01-22
Successor: Olivier Brandicourt
Filed: January 23, 2024, 6:59 PM ET

On January 22, 2024, Thomas Malley resigned from the Board of Directors (the “Board”) of BeiGene, Ltd. (the “Company”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Olivier Brandicourt was appointed as Director at BeOne Medicines Ltd..

Action: appointed
Role: Director

Exact text from the filing

On January 23, 2024, the Board appointed Olivier Brandicourt, M.D. to the Board to fill the vacancy.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Thomas Malley resigned as Director at BeOne Medicines Ltd..

Action: resigned
Role: Director

Exact text from the filing

On January 22, 2024, Thomas Malley resigned from the Board of Directors (the “Board”) of BeiGene, Ltd. (the “Company”).

View on SEC.gov

BeOne Medicines Ltd. filing history →

Source: SEC EDGAR

accession 0001651308-24-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.